Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03563183 · ClinicalTrials.gov registry record
A Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022
A clinical trial, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- 26,976
- Enrollment target
NCT03563183 is a clinical trial that has completed, run by GlaxoSmithKline. The registered enrollment target is 26,976 participants.
The verdict
NCT03563183 has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- 26,976 participants
- Enrollment target
Study Summary
As part of the ZOSTER-006 and ZOSTER-022 pivotal trials of the HZ/su vaccine, all study participants completed quality of life (QoL) questionnaires. The only questionnaires encoded into the data base were those from participants who developed a suspected shingles episode during the study. The purpose of this study is to allow for the encoding and analysis of questionnaires for all subjects enrolled in ZOSTER-006 and ZOSTER-022. The aim is to assess the baseline frailty of subjects enrolled in these studies and to investigate whether this population is representative of the general population.
Interventions
- OTHER Encoding of data collected in Zoster 006 and Zoster 022 studies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26,976 participants |
| Start Date | 2018-06-05 |
| Est. Completion | 2019-04-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03563183
The ClinicalTrials.gov registry entry for NCT03563183 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 26,976 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Encoding of data collected in Zoster 006 and Zoster 022 studies is the first listed.
NCT03563183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03563183 about?
NCT03563183 is a clinical study titled "A Study to Assess Frailty of Subjects During ZOSTER-006 and ZOSTER-022". As part of the ZOSTER-006 and ZOSTER-022 pivotal trials of the HZ/su vaccine, all study participants completed quality of life (QoL) questionnaires. The only questionnaires encoded into the data base were those from participants who developed a suspected shingles episode during the study. The purpo...
What is the current status of trial NCT03563183?
This trial is currently completed. The enrollment target is 26,976 participants. The study started on 2018-06-05. Estimated completion is 2019-04-30.
What interventions are being tested in trial NCT03563183?
The interventions under investigation include: Encoding of data collected in Zoster 006 and Zoster 022 studies (OTHER).
Who is sponsoring clinical trial NCT03563183?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.